ストックスクリーナーアプリを入手
11.30
0.35%
-0.04
アフターアワーズ：
11.30
前日終値:
$11.34
開ける：
$11.34
24時間の取引高:
7.57M
Relative Volume:
0.99
時価総額：
$13.49B
収益：
$15.05B
当期純損益:
$-883.30M
株価収益率:
-15.27
EPS:
-0.74
ネットキャッシュフロー:
$1.89B
1週間 パフォーマンス:
-3.17%
1か月 パフォーマンス:
-10.25%
6か月 パフォーマンス:
-4.56%
1年 パフォーマンス:
-1.40%
1日の値動き範囲:
$11.23
$11.47
1週間の範囲:
$11.13
$12.02
52週間の値動き範囲:
$9.925
$13.62
Viatris Inc Stock (VTRS) Company Profile
VTRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.30 | 13.49B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-19 | 再開されました | Jefferies | Buy |
| 2023-10-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-06-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2023-04-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-02-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-10 | アップグレード | UBS | Sell → Neutral |
| 2022-11-08 | アップグレード | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 再開されました | Jefferies | Hold |
| 2022-06-14 | 開始されました | UBS | Sell |
| 2022-05-10 | ダウングレード | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 開始されました | Citigroup | Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-03-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 開始されました | Argus | Hold |
| 2020-12-14 | 開始されました | Bernstein | Mkt Perform |
すべてを表示
Viatris Inc (VTRS) 最新ニュース
EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com
Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights
Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com
Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance
Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? - Insider Monkey
Viatris Enters Oversold Territory - Nasdaq
Viatris Stock: Is VTRS Outperforming the Healthcare Sector? - MSN
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Another Disappointing Drug Import Alert from India - The People's Pharmacy
When (VTRS) Moves Investors should Listen - Stock Traders Daily
US FDA Blocks 11 Viatris Products, Except Four With Shortage Concerns - News & Insights
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Con - GuruFocus.com
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Maternal Mental Health Market Is Booming Worldwide 2025-2032 | - openPR
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris (VTRS) Shares Cross 4% Yield Mark - Nasdaq
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes (NASDAQ:VTRS) - Seeking Alpha
FDA Blocks Viatris US Products With India Facility Import Alert - News & Insights
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - FiercePharma
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Viatris Inc. stock falls Monday, still outperforms market - MarketWatch
Maternal Mental Health Market Set to Witness Significant Growth by 2024-2031: Canopie, Pfizer Inc, Viatris - EIN News
Viatris Inc. stock falls Friday, still outperforms market - MarketWatch
Viatris Stock: Is VTRS Outperforming The Healthcare Sector? - Barchart
Viatris receives FDA warning letter for 11 drugs made at India plant - MSN
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris faces FDA import restrictions at Indian facility - The Pharma Letter
Viatris confirms receipt of warning letter, import alert for India facility - TipRanks
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - Kilgore News Herald
US FDA restricts imports of some Viatris drugs made at India facility - Reuters
FDA restricts import of certain Viatris products due to plant violations - Investing.com UK
Viatris says India plant hit with FDA warning letter, import ban on 11 products - FiercePharma
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve
Cenerimod shows promise in SLE trial, Viatris reports - Investing.com
Viatris announces publication of CARE study results - TipRanks
Viatris Inc (VTRS) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
0.94%
大文字化:
|
ボリューム (24 時間):